FORM 4

Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C	20549
vasilington,	D.C.	20049

to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES IN BENEFICIAL	OWNERSHIP
obligations may continue. See		

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Gordon Murdo					2. Issuer Name and Ticker or Trading Symbol AMGEN INC [AMGN]									(Che	eck all app Direc	tionship of Reportii all applicable) Director Officer (give title		son(s) to Is 10% Over (s	wner
(Last) (First) (Middle) ONE AMGEN CENTER DRIVE					3. Date of Earliest Transaction (Month/Day/Year) 03/06/2023									- 2	belov			below)	
(Street) THOUS	AND CA	A 9	01320		4. If <i>F</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(St	ate) (2	Zip)			1 6350													
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date				2. Transa Date (Month/Da	Execution		Date,	3. Transaction Code (Instr. 8)					(A) or 3, 4 and	Benefi	ties cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code			v	Amount	(A) (D)	or	Price	Transa	action(s) 3 and 4)			(IIIsti. 4)			
Common Stock 03/06/				03/06/	/2023		A		7,947	1	A	\$ <mark>0</mark>	55,0	,621(1)(2)		D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
Security or Exercise (Month/Day/Year) if any		med on Date, Day/Year)	4. Transaction Code (Instr. 8)		of Deriv	r osed) r. 3, 4	6. Date Exerci Expiration Dat (Month/Day/You		te	Amount of Securities Underlying Derivative Security (Ins 3 and 4)		ount	3. Price of Derivative Security Instr. 5)			10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		

Explanation of Responses:

- 1. These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,534 RSUs which vest in one installment on 5/3/2023; 2,325 RSUs which vest in installments of 1,145 on 5/5/2023 and 1,180 on 5/5/2024; 4,172 RSUs which vest in installments of 1,376 on 4/30/2023, 1,377 on 4/30/2024 and 1,419 on 4/30/2025; and 4,330 vest in installments of 1,376 on 1,376 on 1,376 on 1,376 on 1,377 on 1,1,428 on 5/2/2024, 1,429 on 5/2/2025, and 1,473 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
- 2. These shares include 714 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

/s/ Murdo Gordon

03/08/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.